DB=PGPB; PLUR=YES; OP=ADJ			
L11	(fish adj oil) same (antibod$ or immunoglobulin$ or immunosuppressive$ or rapamycin$)	417	L11
DB=DWPI; PLUR=YES; OP=ADJ			
L10	(("DE 3781686G")!.ABPN1,NRPN.) .p22-p52.	1	L10
DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L9	(fish adj oil) same (antibod$ or immunoglobulin$ or immunosuppressive$ or rapamycin$)	4	L9
DB=USPT; PLUR=YES; OP=ADJ			
L8	L7 same (antibod$ or immunoglobulin$ or immunosuppressive$ or rapamycin$)	30	L8
L7	(fish adj oil)same(pharmaceutical or therapeutic)same (composition$)	100	L7
L6	(rapamycin$) and(kit$)same (pharmaceutical or therap$ or treat$)same (immunosuppressiv$)	22	L6
L5	(rapamycin$) and(kit$)same (pharmaceutical or therap$ or treat$)same (antibod$)	115	L5
L4	(rapamycin$) and(kit$)same (pharmaceutical or therap$ or treat$)	516	L4
DB=PGPB; PLUR=YES; OP=ADJ			
L3	l1	51	L3
DB=USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L2	L1	25	L2
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L1	(rapamycin$)same (kit$)same (pharmaceutical or therap$ or treat$)	76	L1

END OF SEARCH HISTORY

US 20040202650A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2004/0202650 A1

Gribben et al. (43) Pub. Date: Oct. 14, 2004

(54) METHODS OF INHIBITING T CELL PROLIFERATION OR IL-2 ACCUMULATION WITH CTLA-4 SPECIFIC ANTIBODIES

(76) Inventors: **John G. Gribben**, Brookline, MA (US); **Gordon J. Freeman**, Brookline, MA (US); **Lee M. Nadler**, Newton, MA (US); **Paul D. Rennert**, Holliston, MA (US); **Cindy L. Jellis**, Londonderry, NH (US); **Edward Greenfield**, Randolph, MA (US); **Gary S. Gray**, Brookline, MA (US)

Correspondence Address:
LAHIVE & COCKFIELD, LLP.
28 STATE STREET
BOSTON, MA 02109 (US)

(21) Appl. No.: 10/732,847

(22) Filed: Dec. 9, 2003

Related U.S. Application Data

(62) Division of application No. 08/253,783, filed on Jun. 3, 1994, now Pat. No. 6,719,972.

Publication Classification

(51) Int. Cl.[7] A61K 39/395

(52) U.S. Cl. 424/131.1; 424/144.1

(57) ABSTRACT

Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e.g., for use in purging alloreactive T cells from donor bone marrow prior to bone marrow transplantation to inhibit graft versus host disease.